Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366288 · ClinicalTrials.gov registry record
Study Evaluating PAZ-417 in Healthy Young/Elderly
A clinical trial, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- 56
- Enrollment target
NCT00366288: Completed study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00366288 is a clinical trial that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00366288 has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be assessed.
Interventions
- DRUG PAZ-417
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-03 |
What the finished NCT00366288 record still lists
NCT00366288 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PAZ-417 is the first listed.
NCT00366288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00366288 about?
NCT00366288 is a clinical study titled "Study Evaluating PAZ-417 in Healthy Young/Elderly". This study is to evaluate the safety and tolerability of single, ascending doses of PAZ-417 in healthy young and healthy elderly subjects. The effect of a high fat meal on the metabolism of PAZ-417 will also be studied, along with blood levels of PAZ-417 . Changes in cognitive function will be asses...
What is the current status of trial NCT00366288?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2006-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00366288?
The interventions under investigation include: PAZ-417 (DRUG).
Who is sponsoring clinical trial NCT00366288?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia